New ovarian cancer treatment succeeds in the lab

by Marlen Mursuli
The illustration above shows both cancer and healthy cells in the same microenvironment. Special magneto-electric nanoparticles (MENs), which are loaded with the drug of interest, are administered through intravenous (IV) injection. When an external low-energy magnetic field is turned “on” outside the patient’s body, the pores in the membranes of the cancer cells (in the targeted part of the body) open up while the membranes of the healthy cells remain closed. Thus, the specificity of the targeted drug delivery to the cancer cells is achieved via control by a remote magnetic field on demand.

In a study to be published today in Scientific Reports, researchers from the Florida International University Herbert Wertheim College of Medicine and the FIU College of Engineering and Computing describe what could be a breakthrough in the treatment of ovarian cancer: a novel way to deliver cancer-killing drugs using nanotechnology.

In their lab experiments, Taxol, a chemotherapy drug used to treat , was loaded onto a magneto-electric nanoparticle, and using an electric field the drug penetrated into the completely destroying the tumor within 24 hours, while sparing normal ovarian cells.

"Sparing healthy cells has been a major challenge in the treatment of cancer, especially with the use of Taxol; so in addition to treating the cancer, this could have a huge impact on side-effects and toxicity," said Carolyn Runowicz, M.D., professor of gynecology and obstetrics and executive dean for academic affairs at the Herbert Wertheim College of Medicine.

Ovarian cancer is the deadliest of all . According to the American Cancer Society 14,000 women will die this year from ovarian cancer. This new treatment is the collaborative product of an oncologist and an engineer looking to challenge the odds and save lives.

"This is an important beginning for us. I'm very excited because I believe that it can be applied to other cancers including breast cancer and lung cancer," said Sakhrat Khizroev, Ph.D., professor of electrical and computer engineering at the FIU College of Engineering and Computing.

More information: www.nature.com/srep/2013/131016/srep02953/full/srep02953.html

Related Stories

Biomarkers predict time to ovarian cancer recurrence

Aug 15, 2013

Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated ...

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

11 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

16 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

17 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments